AzTrials
AzTrials

EsophagectomyCIFONCT06911658

Infectious Complications After Esophagectomy

An observational study of Esophagectomy and Postoperative Complications, run by Assistance Publique - Hôpitaux de Paris at 2 sites in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Infectious complications represent the most common postoperative adverse events following esophagectomy for cancer, such as pneumonia (15% of cases). These complications increase immediate risks, lengthen hospital stays, and worsen patient quality of life. Read more about this study

Who is it for?
Ages 18 years and older
How many people
1,029 participants
Where
2 sitesFrance
Study dates
27 Aug 2025to 4 Sep 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Hospitalized patients in intensive care unity.

Who may be able to join

  • Patients over 18 years of age
  • Underwent esophagectomy for cancer between January 1, 2017, and December 31, 2024
  • Scheduled admission to intensive care for postoperative monitoring

Who cannot join

  • Opposition to the use of data

Trial locations and contacts

2 sites in 1 country.

France2 sites
  • Hôpital Saint-Louis - APHP

    Paris, 75010

  • Saint Louis Hospital

    Paris, 75010

Other trials in France

About this study

Official title: Infectious Complications, Associated Factors, and Prognosis After Esophagectomy for Cancer: A French, Multicenter, Retrospective Study - CIFO-study

Infectious complications represent the most common postoperative adverse events following esophagectomy for cancer, such as pneumonia (15% of cases). These complications increase immediate risks, lengthen hospital stays, and worsen patient quality of life.

The population includes patients admitted to intensive care after esophagectomy for cancer between January 1, 2017, and December 31, 2024.

Read more

The study focuses on this population due to the increasing incidence of esophageal cancer, the increased use of surgery for these indications, and the importance of postoperative infections in these complex procedures, despite their understudied nature in the current literature. Identifying modifiable risk factors could lead to corrective measures and thus improve the prognosis of postoperative patients.

The research focuses primarily on the incidence, types, factors, and prognosis associated with the occurrence of infections after esophagectomy for cancer. It also includes an analysis of the pathogens involved, their resistance profiles, and the antibiotic therapies used in first-line probabilistic treatment.

Read the detailed description

The retrospective, multicenter study consists of the retrospective and pseudonymous collection of data from the medical reports of patients, covering the period from January 2017 to December 31, 2024, who were treated in each participating intensive care unit.

The investigators at each participating center will be responsible for screening and including patients, as well as obtaining their non-opposition.

Patients who were hospitalized for esophagectomy will be included, provided there are no exclusion criteria.

The following data will be collected after pseudonymization: only the first letter of the patient's last name and the first letter of their first name will be recorded, along with a study-specific coded number, which will differ for each center and indicate the order of inclusion of subjects. A correspondence table will be kept at each center for a period of 15 years. This table will be stored within each participating center.

At each participating center, data entry will be coordinated by the investigator responsible for the center. The collected data will be pseudonymized and stored in a secure database located at each participating center.

  • If the patient is alive: the patient will be informed about the study. Data collection will begin only after the patient has been informed and only if the patient does not express opposition to the use of their data.
  • If the patient is deceased and the vital status of the patient is known to the investigator: in this case, the investigator will verify in the patient's medical record that the patient has never expressed written opposition to the use of their data for research purposes. If the patient has never objected, their data will be collected.
Keywords
Postoperative infection, Esophagectomy complications
Medical subject headings
Postoperative Complications, Infections, Pneumonia

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of infections after esophagectomy for cancer

    Measured: until the day 28

Secondary outcomes (5)
  1. Number of postoperative infectious episodes per participant, classified by anatomical site, as assessed retrospectively from hospitalization records

    Each infectious episode occurring within 28 days after esophagectomy will be retrospectively identified by review of hospitalization records. The anatomical site of infection (e.g., pulmonary, pleural, mediastinal, urinary, abdominal, surgical wound, bloodstream) will be determined based on the description found in medical documentation.

    The diagnosis of infection will rely on retrospective analysis of recorded clinical signs (e.g., fever), laboratory data (e.g., leukocytosis, elevated CRP), imaging reports (e.g., CT scan, chest X-ray), and physician assessmentsdocumented in the medical file.

    The unit of measure is : number of infectious episodes per participant. The data will be reported as the total number of episodes and their distribution by anatomical site, summarized per participant and overall using descriptive statistics (median [IQR], counts, percentages).

    Measured: until the day 28

  2. Presence of predefined pathogens during postoperative infectious episodes, as assessed retrospectively from hospitalization records

    For each postoperative infectious episode occurring within 28 days after esophagectomy, the presence or absence of specific pathogens will be retrospectively extracted from hospitalization reports using a structured checklist.

    The pathogens are not recorded as free-text entries but as binary variables (Yes/No) based on the presence of documentation in medical reports (microbiology results, discharge summaries, etc.).

    The predefined list includes :

    • Gram-positive cocci : Streptococcus spp., Enterococcus spp., E. faecium, Staphylococcus aureus (including MRSA)
    • Gram-negative bacteria : Haemophilus spp., Enterobacteriaceae (groups 1-3), non-fermenting bacilli (P. aeruginosa, A. baumannii, S. maltophilia)
    • Resistance profiles : ESBL-producing Enterobacteriaceae, carbapenemase-producing organisms
    • Fungi : Yeasts
    • Polymicrobial vs. monomicrobial infections Only pathogens explicitly mentioned in the clinical documentation (culture or PCR results) are recorded. The data are collected usi

    Measured: until the day 28

  3. Association between preoperative and perioperative clinical variables and the occurrence of postoperative infection, as assessed by multivariable logistic regression analysis of hospitalization records

    This outcome aims to explore the association between clinical and surgical factors and the risk of developing at least one infectious episode within 28 days following esophagectomy.

    Postoperative infections will be identified retrospectively based on hospitalization records. A multivariable logistic regression analysis will be conducted, with infection occurrence (Yes/No) as the dependent variable.

    Covariates will include :

    • Demographic characteristics : age and sex
    • Lifestyle factors : tobacco use and alcohol consumption (>2 drinks/day)
    • Nutritional status and general severity : Body Mass Index (BMI), IGS2 score at ICU admission
    • Comorbidities : cardiovascular disease (hypertension, myocardial infarction, congestive heart failure), chronic pulmonary disease, cerebrovascular disease (including stroke or transient ischemic attack), peripheral vascular disease (including aortic aneurysm >6 cm), diabetes (complicated or not), renal failure, liver disease (moderate or severe), dementi

    Measured: until the day 28

  4. Occurrence of major complications (sepsis, septic shock, AKI, ARDS, or death) within 28 days after esophagectomy, as documented in hospitalization records, compared between infected and non-infected patients

    Association between postoperative infection and the occurrence of major complications (sepsis, septic shock, AKI, ARDS, or death), as assessed by logistic regression analyses of hospitalization records.

    Description

    This outcome assesses the relationship between the occurrence of postoperative infection (within 28 days of esophagectomy) and the development of the following complications :

    • Sepsis (according to Sepsis-3)
    • Septic shock (according to Sepsis-3)
    • Acute kidney injury (AKI according to KDIGO)
    • Acute respiratory distress syndrome (ARDS according to the Berlin's definition)
    • Mortality All events will be collected retrospectively from hospitalization records. A logistic regression will be used for each outcome separately to estimate the effect of infection (Yes/No) on the likelihood of each complication.

    Unit of measure : Odds Ratio (OR) with 95% Confidence Interval for each complication

    Measured: until day 28

  5. Association between postoperative infection and length of hospital stay, as assessed by linear regression analysis of hospitalization records

    Length of hospital stay (in days, from surgery to discharge) will be extracted from hospitalization records.

    A linear regression model will be used to assess whether the occurrence of a postoperative infection is associated with a prolonged hospital stay, adjusted for relevant covariates.

    Unit of measure : Median difference in number of days, with 95% Confidence Interval

    Measured: until day 28

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Apr 2025
  2. Study start27 Aug 2025
  3. Primary completion4 Sep 2026
  4. Study completion4 Sep 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
1,029 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06911658
Sponsor's protocol ID
APHP250038
Acronym
CIFO
Status last verified
Sep 2026
First submitted
13 Mar 2025
Last updated
14 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Esophagectomy and Postoperative Complications, run by Assistance Publique - Hôpitaux de Paris at 2 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of infections after esophagectomy for cancer (time frame: until the day 28). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Sep 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in